India's Biocon begins marketing psoriasis drug Alzumab

India's Biocon has launched Alzumab (Itolizumab), an anti-CD6 antibody designed to treat chronic plaque psoriasis. "Biocon's Alzumab (Itolizumab) is the first anti-CD6 monoclonal antibody to be commercialized, an outcome of path breaking research in India," noted Biocon chief Kiran Mazumdar-Shaw. The company is looking for partners to expand commercialization of the therapy around the globe. Release (PDF)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.